Antacids Market

Executive Summary

Antacids Market was valued at US $6.62 billion in 2021 and is projected to grow at 4.22% CAGR over the forecast period to reach US $8.48 billion by 2027. Antacids Market represented US $0.52 billion opportunity over 2019-2021 and estimated to create US $1.86 billion opportunity in 2027 over 2021.

Antacids from Consainsights analyses the Antacids Market in the Life Sciences industry over the forecast period to 2027.

Antacids research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Antacids segmentation includes Formulation Type, Distribution Channel and Geography.

Based on the Formulation Type, the Antacids analysis covers Tablet, Powder, Others.

In Formulation Type segment, Tablet segment has highest cagr growth of 3.74%.

Based on the Distribution Channel, the Antacids analysis covers Hospital Pharmacies, E-Commerce, Others.

In Distribution Channel segment, Hospital Pharmacies segment has highest cagr growth of 3.74%.

Based on the region, the Antacids analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Sun Pharmaceuticals Ltd, Sanofi S.A, WellSpring Pharmaceutical Corporation, Advance Pharmaceutical Inc., CVS Pharmacy, Safetec of America, Inc., Pfizer inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., Reckitt Benckiser Group plc., Takeda Pharmaceutical Company Limited, Procter & Gamble and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Formulation Type

Introduction

In 2021, Tablet segment has the highest revenue of US $4.76 billion and is expected to grow at CAGR of 3.74% by 2027 Tablet segment has highest cagr growth of 3.74%.

Tablet

Tablet segment was valued at US $4.38 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $6.10 billion by 2027. Tablet segment represented US $0.38 billion opportunity over 2019-2021 and estimated to create US $1.34 billion opportunity in 2027 over 2021.

Powder

Powder segment was valued at US $1.64 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $2.28 billion by 2027. Powder segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.50 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.08 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $0.10 billion by 2027. Others segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacies segment has the highest revenue of US $2.52 billion and is expected to grow at CAGR of 3.74% by 2027 Hospital Pharmacies segment has highest cagr growth of 3.74%.

Hospital Pharmacies

Hospital Pharmacies segment was valued at US $2.32 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $3.23 billion by 2027. Hospital Pharmacies segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.71 billion opportunity in 2027 over 2021.

E-Commerce

E-Commerce segment was valued at US $2.27 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $3.16 billion by 2027. E-Commerce segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $1.50 billion in 2019 and is projected to grow at 3.74% CAGR over the forecast period to reach US $2.09 billion by 2027. Others segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.46 billion opportunity in 2027 over 2021.